In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 |
| 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | S-1/A |
Revenues: |
Billing Services | 2.8 | 4.9 | 1.6 | | | | |
OTC and Prescription Medicine | 0.7 | 1.4 | 0.5 | | | | |
Total revenues [+] | 3.5 | 6.3 | 2.1 | 0.0 | 0.0 | 0.1 | 0.0 |
Products | | | | | | 0.1 | 0.0 |
Net interest income | | | | | | 0.0 | |
Revenue growth [+] | -44.8% | 206.2% | 22808.3% | -60.8% | -61.8% | 370.1% | |
Billing Services | -43.4% | 208.2% | | | | | |
OTC and Prescription Medicine | -50.1% | 199.0% | | | | | |
Cost of goods sold | 0.5 | 1.0 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross profit | 3.0 | 5.3 | 1.7 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross margin | 85.9% | 83.7% | 83.9% | 63.7% | 72.0% | 82.8% | 10.2% |
Selling, general and administrative [+] | 2.0 | 3.6 | 1.5 | 0.1 | 0.1 | 0.2 | 0.3 |
General and administrative | 2.0 | 3.6 | 1.5 | 0.1 | 0.1 | 0.2 | 0.3 |
Other operating expenses | 1.5 | 0.5 | 0.1 | 0.0 | 0.0 | 0.0 | |
EBITDA [+] | -0.1 | 1.7 | 0.2 | | | | |
EBITDA growth | -104.0% | 821.5% | -225.2% | 117.9% | -65.1% | -43.3% | |
EBITDA margin | -1.9% | 26.8% | 8.9% | -1627.0% | -292.4% | -320.3% | -2656.8% |
Depreciation | 0.0 | 0.0 | 0.0 | | | | |
EBITA | -0.1 | 1.7 | 0.2 | -0.1 | -0.1 | -0.2 | -0.3 |
EBITA margin | -2.2% | 26.6% | 8.9% | -1627.0% | -292.4% | -320.3% | -2656.8% |
Amortization of intangibles | 0.4 | 0.5 | 0.1 | | | | |
EBIT [+] | -0.5 | 1.2 | 0.1 | -0.1 | -0.1 | -0.2 | -0.3 |
EBIT growth | -142.8% | 1828.7% | -143.0% | 117.9% | -65.1% | -43.3% | |
EBIT margin | -14.9% | 19.2% | 3.1% | -1627.0% | -292.4% | -320.3% | -2656.8% |
Interest expense | 1.5 | 1.8 | 0.3 | 0.0 | | | 0.0 |
Interest expense | 1.5 | 1.8 | 0.3 | 0.0 | | | 0.0 |
Other income (expense), net [+] | | | | 0.0 | | | 0.0 |
Other non-ooperating expenses | 1.5 | 1.8 | 0.3 | | | | |
Pre-tax income | -2.0 | -0.6 | -0.2 | -0.1 | -0.1 | -0.2 | -0.3 |
Income taxes | -0.5 | 0.1 | -0.6 | 0.0 | 0.0 | 0.0 | 0.0 |
Tax rate | 27.0% | | 308.2% | 0.0% | 0.0% | 0.0% | 0.0% |
Net income | -1.5 | -0.7 | 0.4 | -0.1 | -0.1 | -0.2 | -0.3 |
Net margin | -42.1% | -10.6% | 21.2% | -1611.2% | -292.4% | -320.3% | -2669.6% |
|
Basic EPS [+] | ($0.06) | ($0.03) | $0.02 | ($0.01) | $0.00 | ($0.01) | ($0.02) |
Growth | 119.0% | -227.0% | -378.9% | 110.9% | -65.9% | -51.3% | |
Diluted EPS [+] | ($0.06) | ($0.03) | $0.02 | ($0.01) | $0.00 | ($0.01) | ($0.02) |
Growth | 119.0% | -227.0% | -378.9% | 110.9% | -65.9% | -51.3% | |
|
Shares outstanding (basic) [+] | 22.9 | 22.9 | 18.9 | 17.5 | 17.1 | 16.7 | 14.4 |
Growth | 0.0% | 21.0% | 7.8% | 2.3% | 2.5% | 15.7% | |
Shares outstanding (diluted) [+] | 22.9 | 22.9 | 18.9 | 17.5 | 17.1 | 16.7 | 14.4 |
Growth | 0.0% | 21.0% | 7.8% | 2.3% | 2.5% | 15.7% | |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |